On Invalid Date, Halozyme Therapeutics (NASDAQ: HALO) reported Q1 2023 earnings per share (EPS) of $0.29, up 34.09% year over year. Total Halozyme Therapeutics earnings for the quarter were $39.62 million. In the same quarter last year, Halozyme Therapeutics's earnings per share (EPS) was $0.44.
As of Q2 2023, Halozyme Therapeutics's earnings has grown -56.82% year over year. This is 62.65 percentage points lower than the US Biotechnology industry earnings growth rate of 5.83%. Halozyme Therapeutics's earnings in the past year totalled $181.64 million.
What is HALO's earnings date?
Halozyme Therapeutics's earnings date is Invalid Date. Add HALO to your watchlist to be reminded of HALO's next earnings announcement.
What was HALO's revenue last quarter?
On Invalid Date, Halozyme Therapeutics (NASDAQ: HALO) reported Q1 2023 revenue of $162.14 million up 38.25% year over year. In the same quarter last year, Halozyme Therapeutics's revenue was $117.28 million.
What was HALO's revenue growth in the past year?
As of Q2 2023, Halozyme Therapeutics's revenue has grown 49.5% year over year. This is 20.28 percentage points lower than the US Biotechnology industry revenue growth rate of 69.78%. Halozyme Therapeutics's revenue in the past year totalled $704.98 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.